Alpha 2.0
Login Register
» Authors » Nikolaj Bak

Nikolaj Bak

Explore the profile of Nikolaj Bak including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 26
Citations 420
Followers 0
Related Specialties
Psychiatry
Psychology
Endocrinology
Top 10 Co-Authors
Birte Y Glenthoj
Bjorn H Ebdrup
Egill Rostrup
Birgitte Fagerlund
Mette O Nielsen
Bob Oranje
Brian V Broberg
Filip K Knop
Lars K Hansen
Bruce J Kinon
Published In
Diabetes Obes Metab
Schizophr Res Cogn
Psychol Med
Biol Psychiatry
J Psychopharmacol
Affiliations
Soon will be listed here.
Recent Articles
1.
Clustering of antipsychotic-naïve patients with schizophrenia based on functional connectivity from resting-state electroencephalography
Ambrosen K, Fredriksson F, Anhoj S, Bak N, van Dellen E, Dominicus L, et al.
Eur Arch Psychiatry Clin Neurosci . 2023 Feb; 273(8):1785-1796. PMID: 36729135
Schizophrenia is associated with aberrations in the Default Mode Network (DMN), but the clinical implications remain unclear. We applied data-driven, unsupervised machine learning based on resting-state electroencephalography (rsEEG) functional connectivity...
2.
Clinical correlates of early onset antipsychotic treatment resistance
Fonseca de Freitas D, Agbedjro D, Kadra-Scalzo G, Francis E, Ridler I, Pritchard M, et al.
J Psychopharmacol . 2022 Oct; 36(11):1226-1233. PMID: 36268751
Background: There is evidence of heterogeneity within treatment-resistant schizophrenia (TRS), with some people not responding to antipsychotic treatment from illness onset and others becoming treatment-resistant after an initial response period....
3.
A predictor model of treatment resistance in schizophrenia using data from electronic health records
Kadra-Scalzo G, Fonseca de Freitas D, Agbedjro D, Francis E, Ridler I, Pritchard M, et al.
PLoS One . 2022 Sep; 17(9):e0274864. PMID: 36121864
Objectives: To develop a prognostic tool of treatment resistant schizophrenia (TRS) in a large and diverse clinical cohort, with comprehensive coverage of patients using mental health services in four London...
4.
Using a statistical learning approach to identify sociodemographic and clinical predictors of response to clozapine
Fonseca de Freitas D, Kadra-Scalzo G, Agbedjro D, Francis E, Ridler I, Pritchard M, et al.
J Psychopharmacol . 2022 Feb; 36(4):498-506. PMID: 35212240
Background: A proportion of people with treatment-resistant schizophrenia fail to show improvement on clozapine treatment. Knowledge of the sociodemographic and clinical factors predicting clozapine response may be useful in developing...
5.
A machine-learning framework for robust and reliable prediction of short- and long-term treatment response in initially antipsychotic-naïve schizophrenia patients based on multimodal neuropsychiatric data
Ambrosen K, Skjerbaek M, Foldager J, Axelsen M, Bak N, Arvastson L, et al.
Transl Psychiatry . 2020 Aug; 10(1):276. PMID: 32778656
The reproducibility of machine-learning analyses in computational psychiatry is a growing concern. In a multimodal neuropsychiatric dataset of antipsychotic-naïve, first-episode schizophrenia patients, we discuss a workflow aimed at reducing bias...
6.
Rasch analysis of the PANSS negative subscale and exploration of negative symptom trajectories in first-episode schizophrenia - data from the OPTiMiSE trial
Baandrup L, Allerup P, Nielsen M, Bak N, During S, Leucht S, et al.
Psychiatry Res . 2020 May; 289:112970. PMID: 32438207
The observed heterogeneity in negative symptom treatment response may be partly attributable to inadequate measurement tools or limitations in methods of analysis. Previous Item Response Theory models of the Positive...
7.
Sexual dysfunction and hyperprolactinemia in schizophrenia before and after six weeks of D receptor blockade - An exploratory study
During S, Nielsen M, Bak N, Glenthoj B, Ebdrup B
Psychiatry Res . 2019 Feb; 274:58-65. PMID: 30780063
Sexual side-effects along with antipsychotic treatment may be linked to hyperprolactinemia and dopamine D receptor blockade. High prevalence of sexual dysfunction in un-medicated patients challenges the notion of sexual dysfunction...
8.
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density
Eriksson R, Broberg B, Ishoy P, Bak N, Andersen U, Jorgensen N, et al.
Front Psychiatry . 2019 Feb; 9:781. PMID: 30745885
Low bone mineral density (BMD) may constitute an underestimated comorbidity in schizophrenia patients undergoing long-term antipsychotic treatment. Glucagon-like peptide 1 (GLP-1) receptor agonists are antidiabetic drugs, which may also affect...
9.
Accuracy of diagnostic classification algorithms using cognitive-, electrophysiological-, and neuroanatomical data in antipsychotic-naïve schizophrenia patients
Ebdrup B, Axelsen M, Bak N, Fagerlund B, Oranje B, Raghava J, et al.
Psychol Med . 2018 Dec; 49(16):2754-2763. PMID: 30560750
Background: A wealth of clinical studies have identified objective biomarkers, which separate schizophrenia patients from healthy controls on a group level, but current diagnostic systems solely include clinical symptoms. In...
10.
The impact of schizophrenia and intelligence on the relationship between age and brain volume
Jensen M, Bak N, Rostrup E, Nielsen M, Pantelis C, Glenthoj B, et al.
Schizophr Res Cogn . 2018 Oct; 15:1-6. PMID: 30302317
Age has been shown to have an impact on both grey (GM) and white matter (WM) volume, with a steeper slope of age-related decline in schizophrenia compared to healthy controls....